Aktis Oncology
AKTS
17.53
-0.47
-2.64%
Aktis Oncology
US · AKTS
#3249 by market cap
Listed 2026
17.53
-0.47
-2.64%
Live - 5344 symbols - heartbeat 220s ago
· 2026-10-08 09:58
Pre-market
17.87
-0.72%
After-hours
18.00
0.00%
- Market cap
- 974.75M
- P/E (TTM)i
- -12.81
- P/Bi
- 2.01
- EPSi
- -1.15
- Div yieldi
- 0.00%
- 52W posi
- 14%
Reader sentiment
Are you bullish or bearish on AKTS?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is 0.59, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 4 years
Latest year +336.92% YoY
Margins
- Operating margin
- -1,149.52%
- Net margin
- -980.93%
Key ratios & quality
- Altman Z-Scorei
- 0.59
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | -- | 0 | 1.49M | 6.50M |
| Gross profit | -- | -- | -- | -- |
| Selling & admin expenses | 5.11M | 7.68M | 11.31M | 12.60M |
| Research & development | 14.30M | 25.92M | 40.95M | 67.45M |
| Operating profit | -19.76M | -34.79M | -52.05M | -74.68M |
| Pretax profit | -17.93M | -28.64M | -43.98M | -63.73M |
| Tax | -- | -- | -- | -- |
| Net profit | -17.93M | -28.64M | -43.98M | -63.73M |
| Basic EPS | -1 | -1 | -1 | -1 |
| Diluted EPS | -0.51 | -0.82 | -1.26 | -1.21 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 1.45M | 1.60M | 1.58M | 1.87M | 3.23M | 3.38M |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 3.35M | 3.68M | 3.06M | 2.51M | 5.34M | 6.40M |
| Research & development | 15.86M | 18.63M | 16.47M | 16.49M | 20.04M | 25.28M |
| Operating profit | -18.14M | -20.96M | -18.20M | -17.38M | -22.71M | -28.90M |
| Pretax profit | -14.99M | -18.08M | -15.53M | -15.14M | -18.33M | -24.14M |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -14.99M | -18.08M | -15.53M | -15.14M | -18.33M | -24.14M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.43 | -0.34 | -0.30 | -0.29 | -0.38 | -0.44 |
Balance sheet
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total current assets | 132.48M | 100.20M | 300.85M | 230.31M |
| Cash & ST investments | 128.60M | 97.86M | 297.17M | 226.79M |
| Inventory | -- | -- | -- | -- |
| Total assets | 138.32M | 122.36M | 326.18M | 264.89M |
| Total current liabilities | 5.28M | 6.24M | 18.82M | 31.24M |
| Short-term debt | 854.00K | 1.53M | 1.30M | 1.32M |
| Long-term debt | -- | -- | -- | -- |
| Total liabilities | 157,552,000.00 | 168,661,000.00 | 413,984,000.00 | 411,034,000.00 |
| Total equity | -19.23M | -46.31M | -87.80M | -146.15M |
| Retained earnings | -20.21M | -48.85M | -92.83M | -156.56M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | -- | -- | 249.42M | 230.31M | 543.94M | 524.54M |
| Cash & ST investments | -- | -- | 246.22M | 226.79M | 538.48M | 517.32M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | -- | -- | 279.04M | 264.89M | 576.80M | 557.60M |
| Total current liabilities | -- | -- | 26.91M | 31.24M | 27.91M | 32.13M |
| Short-term debt | -- | -- | 1.37M | 1.32M | 1.43M | 1.48M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | -- | -- | 411,430,000.00 | 411,034,000.00 | 70,693,000.00 | 72,758,000.00 |
| Total equity | -- | -- | -132.39M | -146.15M | 506.11M | 484.84M |
| Retained earnings | -- | -- | -141.43M | -156.56M | -174.89M | -199.03M |
Cash flow
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Operating cash flow | -18.13M | -30.00M | 14.76M | -64.13M |
| Depreciation & amortization | 445.00K | 1.12M | 1.58M | 2.33M |
| Free cash flow | -20.43M | -33.77M | 11.90M | -73.71M |
| Dividends paid | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- |
| Ending cash balance | 129.49M | 30.66M | 38.31M | 38.93M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -17.48M | -16.18M | -15.22M | -15.24M | -24.24M | -20.59M |
| Depreciation & amortization | 484.00K | 552.00K | 598.00K | 695.00K | 652.00K | 879.00K |
| Free cash flow | -19.38M | -17.72M | -17.23M | -19.40M | -26.10M | -21.85M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 0 | -- | -- | 339.78M | 0 |
| Ending cash balance | 59.40M | 111.36M | 181.40M | 38.93M | 372.78M | 83.64M |
Returns & efficiency
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| ROE %i | -- | -- | -- | -- |
| ROA %i | -12.96 | -21.97 | -19.61 | -21.56 |
| ROIC %i | -- | -- | -- | -- |
| 5-year avg ROE %i | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -3,500.34 | -1,149.52 |
| FCF / sales %i | -- | -- | 800.27 | -- |
| Current ratioi | 25.11 | 16.07 | 15.98 | 7.37 |
| Quick ratioi | 24.38 | 15.69 | 15.79 | 7.26 |
| Debt / assetsi | 1.28 | 10.95 | 3.68 | 4.36 |
| LT debt / equityi | -- | -- | -- | -- |
| Interest coveragei | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -- | -- | -13.25 | -15.09 |
| ROA %i | -- | -- | -19.69 | -21.56 | -11.63 | -13.12 |
| ROIC %i | -- | -- | -- | -- | -15.32 | -17.58 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -1,311.94 | -1,149.52 | -957.44 | -866.63 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | -- | -- | 9.27 | 7.37 | 19.49 | 16.33 |
| Quick ratioi | -- | -- | 9.15 | 7.26 | 19.29 | 16.10 |
| Debt / assetsi | -- | -- | 4.25 | 4.36 | 2.01 | 2.02 |
| LT debt / equityi | -- | -- | -- | -- | 2.00 | 2.01 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Research and development of targeted radiopharmaceuticals to treat a broad range of solid tumor100.00%
Quote time 2026-10-08 09:58:12 · For reference only, not investment advice and not tailored to your situation.